| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA835: fostamatinib for treating refractory chronic immune thrombocytopenia |
|
Medicine details |
|
| Medicine name | fostamatinib disodium (Tavlesse®) |
| Formulation | 100mg and 150mg film coated tablets |
| Reference number | 2460 |
| Indication | Treatment of chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments |
| Company | Grifols |
| BNF chapter | Nutrition & blood |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 13/08/2021 |
| NICE guidance | TA835: fostamatinib for treating refractory chronic immune thrombocytopenia |
| Commercial arrangement | PAS |